Eli Lilly and Co (LLY)

LLY (NYSE:Drugs) EQUITY
$70.17
pos +0.00
+0.00%
Today's Range: 69.91 - 70.50 | LLY Avg Daily Volume: 4,755,100
Last Update: 02/27/15 - 4:00 PM EST
Volume: 0
YTD Performance: 1.71%
Open: $0.00
Previous Close: $70.03
52 Week Range: $56.81 - $75.10
Oustanding Shares: 1,111,103,942
Market Cap: 77,810,609,058
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 6 6
Moderate Buy 1 1 1 0
Hold 9 9 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 1
Mean Rec. 2.23 2.23 2.10 2.29
Latest Dividend: 0.50
Latest Dividend Yield: 2.86%
Dividend Ex-Date: 02/11/15
Price Earnings Ratio: 31.40
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
31.40 31.50 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.23% 17.85% 79.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue -15.10 -0.19 -0.07
Net Income -49.00 -0.45 -0.18
EPS -48.50 -0.43 -0.17
Earnings for LLY:
EBITDA 4.71B
Revenue 19.62B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.77 $0.75 $3.16 $3.65
Number of Analysts 4 4 12 9
High Estimate $0.79 $0.77 $3.22 $3.96
Low Estimate $0.72 $0.74 $3.10 $3.40
Prior Year $0.70 $0.68 $2.78 $3.16
Growth Rate (Year over Year) 10.00% 11.03% 13.73% 15.38%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

updateLeerink Healthcare Conf.

Feb 11, 2015 | 6:41 AM EST

Leerink Global Healthcare Conference (Day 1 of 2) - 02/11/15 - 02/12/15 New York, NY

By

Gary Dvorchak

 | Feb 9, 2015 | 10:00 AM EST

Should you be tempted by the energy names?

bullishEli Lilly upgraded at Goldman

Jan 15, 2015 | 7:08 AM EST

LLY was upgraded to Neutral, Goldman Sachs said. $70 price target. Company is improving margins and can deliver double-digit annual earnings growth in the next few years. 

bearishEli Lilly downgraded at BofA/Merrill

Jan 9, 2015 | 7:08 AM EST

LLY was downgraded to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $74 price target. 

bearishEli Lilly downgraded at Deutsche

Jan 8, 2015 | 8:01 AM EST

LLY was downgraded from Buy to Hold, Deutsche Bank said. $75 price target. Valuation call, as the stock gained 35% in 2014. 

bullishEli Lilly upgraded at Jefferies

Jan 8, 2015 | 7:48 AM EST

LLY was upgraded to Buy, Jefferies said. $80 price target. Company has an attractive pipeline and can expand margins. 

By

Doug Kass

 | Jan 7, 2015 | 7:38 AM EST
Break in!
By

Doug Kass

 | Jan 7, 2015 | 7:10 AM EST
The rundown.

bullishEli Lilly numbers boosted at Leerink

Dec 22, 2014 | 7:59 AM EST

Shares of LLY now seen reaching $76, according to Leerink Partners. Estimates also upped, given the company's solid clinical pipeline. Outperform rating. 

By

Jim Cramer

 | Dec 15, 2014 | 7:08 AM EST

Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.

Reports on Tuesday. I am getting a little concerned on how the 2015 guidance will come in....
Soz doing some more good stuff on retail today-- I loved the JCP piece.. Remember you can ...
Despite a big upgrade from Credit Suisse(from Neutral to Outperform)FDX is relatively...
The Market Vectors Gold Miners ETF (GDX) chart continues to exhibit characteristics of a c...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.